Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Natera CEO Steven Chapman sells $526k in common stock

Natera CEO Steven Chapman sells $526k in common stock

Natera's CEO Steven Chapman sold approximately $526,143 worth of company stock on October 1, 2026. The transaction involved the sale of 1,273 shares at $413.31 per share. After this sale, Mr. Chapman still owned 96,926 shares of Natera. This move comes as the company's stock approaches a 52-week high of $427.47, having gained 145% over the past year.

However, investing experts suggest Natera's stock may be overvalued relative to its fair value estimate. The sale was conducted under a Rule 10b5-1 trading plan that Chapman established in December 2023, with amendments made in December 2024 and March 2026. Natera recently reported strong financial results, with revenue surpassing analyst expectations and the company raising its revenue guidance for the year.

The company has also seen regulatory wins and record test volumes. Analysts at RBC Capital increased their price target for Natera to $460 and maintain an Outperform rating, while Rothschild Redburn initiated coverage with a Buy rating and a price target of $385. These developments highlight Natera's leadership in the minimal residual disease testing market, including its Signatera test and a multi-cancer early detection screening test.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →

More in Finance & Markets

More from Saturday 3 October →